SOUTH SAN FRANCISCO, Calif., April 5, 2022– Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
SOUTH SAN FRANCISCO, Calif., March 30, 2022– Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
SOUTH SAN FRANCISCO, Calif., March 3, 2022– Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
- Promising STRO-002 initial data on Phase 1 dose-expansion cohort were reported in January 2022, providing initial insights on a go-forward dosing regimen and biomarker enrichment strategy - - Cash, cash equivalents and marketable securities totaled $229.5 million as...
SOUTH SAN FRANCISCO, Calif., Jan. 6, 2022– Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...
- 33% Objective Response Rate (ORR) was observed in 33 RECIST evaluable patients across all FolRα expression levels and both dose levels. - Dose response was observed, with a 47% ORR in 17 patients who started at the 5.2 mg/kg dose level. - Tumor proportion score...
- Dr. Naumann and Sutro management to discuss interim data on the STRO-002 Phase 1 dose-expansion cohort at Company event scheduled for Wednesday, Jan. 5, 2022 at 5 pm ET, or 2 pm PT SOUTH SAN FRANCISCO, Calif., Dec. 27, 2021 – Sutro Biopharma, Inc. (“Sutro”),...
- Tasly obtains exclusive development and commercialization rights for STRO-002 for Greater China - - License includes a $40 million upfront payment to Sutro, and potentially up to $345 million in development and commercial milestone payments - - Partnership builds on...
– Nonclinical data for STRO-002 and STRO-001 are shared in two oral presentations at the 63rd American Society of Hematology Annual Meeting SOUTH SAN FRANCISCO, Calif, Dec. 13, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development...
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
